EP300 and small cell lung carcinoma: A 2024 study looking at SCLC tumor evolution throughout treatment found that patients with mutations in the lysine acetyltransferase genes CREBBP and EP300 have an elevated risk of disease recurrence, implicating these genes in therapeutic resistance [13].